1. Home
  2. RXRX vs WGS Comparison

RXRX vs WGS Comparison

Compare RXRX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recursion Pharmaceuticals Inc.

RXRX

Recursion Pharmaceuticals Inc.

HOLD

Current Price

$3.50

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$65.84

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXRX
WGS
Founded
2013
2017
Country
United States
United States
Employees
N/A
1300
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
RXRX
WGS
Price
$3.50
$65.84
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$7.50
$120.71
AVG Volume (30 Days)
10.4M
653.2K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
14.79
N/A
EPS
N/A
N/A
Revenue
$74,681,000.00
N/A
Revenue This Year
$12.11
$29.98
Revenue Next Year
$82.52
$25.92
P/E Ratio
N/A
$1,251.58
Revenue Growth
26.92
N/A
52 Week Low
$2.80
$55.17
52 Week High
$7.18
$170.87

Technical Indicators

Market Signals
Indicator
RXRX
WGS
Relative Strength Index (RSI) 51.04 45.72
Support Level $2.89 $56.24
Resistance Level $3.99 $96.34
Average True Range (ATR) 0.17 4.37
MACD 0.04 1.32
Stochastic Oscillator 52.41 54.27

Price Performance

Historical Comparison
RXRX
WGS

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: